The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Addressing global disparities in the treatment and diagnosis of CLL
Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, discusses global disparities in access to treatment and diagnostics for patients with chronic lymphocytic leukemia (CLL), highlighting the significant improvements in life expectancy for those in high-income countries due to targeted therapies. She emphasizes the importance of patient advocacy and education to address these inequalities, particularly in low- and middle-income countries where awareness and resources are lacking. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Beigene, AbbVie, Adaptive Biotechnologies, AstraZeneca, Exact Sciences, Janssen, Roche; Research funding: AstraZeneca, Janssen; Advisory boards: Janssen, BeiGene; Other: In-kind contributions from Illumina and Oxford Nanopore Technologies, Founder of SERENOx.
